Hematology Round Up #EHA24

Welcome to this Hematology Round Up from #EHA24
WE have focused on on Hematologic malignancies with abstracts presented on June 15nd, 2024

The first presentation was abstract s100
This Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) .
Presented by Dr. Facon
This trial presentation had a concomitant publication on the @NEJM
at #ASCO24 last week
https://lnkd.in/d2dRh6Hp



The Second presentation was abstract S101

THE LANDSCAPE OF TP53 MUTATIONS AND THEIR PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKEMIA

https://lnkd.in/dYg6DqPT

The Next presentation was abstract S102

FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA


https://lnkd.in/d2ZM6Z4Q

The Next presentation is abstract S103

ASCIMINIB (ASC) PROVIDES SUPERIOR EFFICACY AND EXCELLENT SAFETY AND TOLERABILITY VS TYROSINE KINASE INHIBITORS (TKI) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN THE PIVOTAL ASC4FIRST STUDY


https://lnkd.in/dxiets8m

Our final Presentation is Late breaking abstract 3438

GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)

https://lnkd.in/dMWxnyF4

Thank you for your attention and enjoy #EHA24

Disclosure: This Hematology Round Up was supported by Sanofi